Ron J Bahar1, Brynie S Collins, Barry Steinmetz, Marvin E Ament. 1. Department of Pediatrics, Division of Gastroenterology, Hepatology, and Nutrition, UCLA Geffen School of Medicine, Los Angeles, CA 91316, USA. bahar@bizla.rr.com
Abstract
OBJECTIVES: To determine the efficacy of amitriptyline (AMI) in treating irritable bowel syndrome (IBS) in adolescents. STUDY DESIGN:Adolescents 12 to 18 years with newly diagnosed IBS were surveyed with a symptom checklist, pain rating scale, visual analog scale, and IBS quality of life (QOL) questionnaire. Subjects were randomized in a double-blinded fashion to receive AMI or placebo, and again completed surveys at 2, 6, 10, and 13 weeks. RESULTS:Thirty-three patients (24 female) were enrolled. Patients receiving AMI were more likely to experience improvement from baseline in overall QOL at 6, 10, and 13 weeks (P = .019, .004, and .013). Patients receiving AMI were also more likely to experience a reduction in IBS-associated diarrhea at 6 and 10 weeks (P = .029 for both), a reduction in periumbilical pain at 10 weeks (P = .018), and a reduction in right lower quadrant pain at 6, 10, and 13 weeks (P = .014, .039, and .004). CONCLUSION:AMI significantly improves overall QOL in adolescents with IBS and should be a therapeutic option for adolescents with this disorder.
RCT Entities:
OBJECTIVES: To determine the efficacy of amitriptyline (AMI) in treating irritable bowel syndrome (IBS) in adolescents. STUDY DESIGN: Adolescents 12 to 18 years with newly diagnosed IBS were surveyed with a symptom checklist, pain rating scale, visual analog scale, and IBS quality of life (QOL) questionnaire. Subjects were randomized in a double-blinded fashion to receive AMI or placebo, and again completed surveys at 2, 6, 10, and 13 weeks. RESULTS: Thirty-three patients (24 female) were enrolled. Patients receiving AMI were more likely to experience improvement from baseline in overall QOL at 6, 10, and 13 weeks (P = .019, .004, and .013). Patients receiving AMI were also more likely to experience a reduction in IBS-associated diarrhea at 6 and 10 weeks (P = .029 for both), a reduction in periumbilical pain at 10 weeks (P = .018), and a reduction in right lower quadrant pain at 6, 10, and 13 weeks (P = .014, .039, and .004). CONCLUSION:AMI significantly improves overall QOL in adolescents with IBS and should be a therapeutic option for adolescents with this disorder.
Authors: Tess E Cooper; Lauren C Heathcote; Jacqui Clinch; Jeffrey I Gold; Richard Howard; Susan M Lord; Neil Schechter; Chantal Wood; Philip J Wiffen Journal: Cochrane Database Syst Rev Date: 2017-08-05
Authors: Alice E Martin; Tamsin V Newlove-Delgado; Rebecca A Abbott; Alison Bethel; Joanna Thompson-Coon; Rebecca Whear; Stuart Logan Journal: Cochrane Database Syst Rev Date: 2017-03-06
Authors: Robert A Arbuckle; Robyn T Carson; Linda Abetz-Webb; Jeffrey Hyams; Carlo Di Lorenzo; Barbara E Lewis; Elizabeth Gargon; Caroline Kurtz; Steven J Shiff; Jeffrey M Johnston Journal: Patient Date: 2014 Impact factor: 3.883